RxDoctor Payments DataLook up a doctor →

David Robertson, MD

Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1659378560

Payments from drug & device makers

$1,712,112in general payments, 2019–2025

Across 2,837 payments — averaging $603.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$567K
  • AstraZeneca$341K
  • Novo Nordisk$242K
  • AbbVie$183K
  • Acella Pharmaceuticals, LLC$61K
  • Bayer$59K
  • plus $260K from 54 others
$310in research payments, 2019–2025

Across 1 payment — averaging $309.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$310

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC1,003$566,764
AstraZeneca(2 entities)408$340,662
Novo Nordisk342$241,528
AbbVie(2 entities)84$182,534
Acella Pharmaceuticals, LLC16$61,486
Bayer42$58,556
Boehringer Ingelheim123$57,820
F. Hoffmann-la Roche AG12$34,650
Amgen(2 entities)134$30,583
Roche Diagnostics Operations, Inc.18$30,285
Sanofi-aventis U.S. LLC62$29,716
Novo Nordisk AS47$26,085
Harmony Biosciences LLC4$13,125
Avion Pharmaceuticals1$9,375
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC26$8,963
Corcept Therapeutics42$3,118
Xeris Pharmaceuticals, Inc.37$3,040
Tandem Diabetes Care, Inc.10$2,650
Regeneron1$1,550
Abbott75$1,431
Roche Diabetes Care, Inc.2$854
Insulet Corporation32$722
Novartis32$672
BETA Bionics, Inc.12$542
Amneal Pharmaceuticals LLC23$487
Mannkind Corporation29$440
Medtronic(2 entities)18$387
Radius Health, Inc.13$294
Bigfoot Biomedical Inc8$279
Amarin Pharma, Inc.15$278
IBSA Pharma Inc.14$258
Madrigal Pharmaceuticals7$202
Esperion Therapeutics, Inc.6$196
BD10$195
Dexcom, Inc.10$177
Recordati_rare_diseases_inc.9$173
Zealand Pharma US, Inc.9$161
Johnson & Johnson11$158
Cequr Corporation7$131
Averitas Pharma Inc.4$114
Kvk-tech, Inc.7$110
Neurocrine Biosciences, Inc.4$103
Currax Pharmaceuticals LLC6$97
Merck6$97
Endo Pharmaceuticals Inc.5$88
Valeritas, Inc.4$77
Eisai Inc.3$67
Intuity Medical Inc1$60
Lifescan, Inc.4$59
Astellas Pharma US Inc3$59
Chiesi USA, Inc.3$55
Kyowa Kirin, Inc.3$53
GRT US Holding, Inc.3$47
Amphastar Pharmaceuticals, Inc.2$45
Ascendis Pharma Endocrinology Inc2$43
Ultragenyx Pharmaceutical Inc.2$41
Embecta Corp.2$40
Ipsen Biopharmaceuticals, Inc2$40
Nevro Corp.2$38
Nalpropion Pharmaceuticals LLC2$33

How this compares

$1,712,112 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$445,783
Medicare patients
788
Services billed
15,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Atlanta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →